Results per Page:
Scientists see foam as starting point of a path to bedside gene therapy
Bioengineer Dr. Matthias Stephan developed a quick-foaming solution that he hopes could one day turn gene therapy into an outpatient procedure
Fred Hutch Cancer Center announces 2025 Evergreen Fund awardees
Nine Fred Hutch researchers receive funding totaling $1.175 million for projects with commercial partnership potential
A foamy way to improve cost, efficiency and safety of gene therapy
From the Stephan Lab, Translational Science and Therapeutics Division
Cost-effective device trains immune cells to kill tumor cells
From the Matthias Stephan Lab, Translational Science & Therapeutics Division
Taking a frothy risk to advance gene therapy
Fred Hutch scientists hope foam could be a cost-reducing, access-enhancing vehicle for delivering future gene therapies
Could a medicated foam make gene therapies more accessible?
In Nature Communications, Fred Hutch bioengineer Matthias Stephan, MD, PhD, reports latest effort to use innovative materials to improve immune-based therapies.
Investment in business development pays dividends for research, patients
Fred Hutch tech transfer specialists help scientists navigate path to bringing innovations to patients
Fred Hutch research a GeekWire Award finalist for Health Innovation of the Year
Other finalists include Fred Hutch spinoffs Adaptive Biotechnologies and Blaze Bioscience
Scientists show thin metal mesh loaded with T cells shrinks solid tumors
Within weeks, CAR T cells targeting ovarian cancer cleared tumors in 70% of treated mice, shows study in Nature Biomedical Engineering. (Note: Images available for media use.)
Cancer immunotherapy gets assist from micro-scale engineering
With new molecular 'handles' and stimulating signals, metallic thin films become a stronghold for cancer-killing immune cells
Reprograming macrophages with nanoparticles
From the Stephan Lab, Clinical Research Division
Nanotech turns pro-tumor immune cells into cancer-killing triple agents
Strategy doubles survival in mice with cancer
Dr. Matthias Stephan named Allen Distinguished Investigator
The $1.5 million award will help translate cutting-edge nanoparticle immunotherapy approach to the clinic
Improving cancer vaccines with T-cell programming nanoparticles
Dr. Matthias Stephan receives grant to develop cancer vaccine–optimizing, TCR-programming nanotechnology
Nanoparticles open doors to cancer-fighting CAR T cells
Tiny liposome-based drug carriers make tumors more vulnerable to targeted immunotherapy
Nanoparticles take immunotherapy in new direction
Hutch scientist to use nanoparticles to reprogram macrophages to tackle brain tumors
10 highlights of Fred Hutch science in 2017
A look back at notable discoveries in cancer immunotherapy, HIV prevention and more
New nanoparticles make targeted, temporary gene therapy possible
‘Hit-and-run’ technology could improve immunotherapy and HIV cure research